Who we are
VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies.
Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.
Our Programmes
Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss.
Who we are
VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies.
Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.
Our Programmes
Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss.
The VasoDynamics Pipeline
The company’s technology is currently differentiated in three formulation platforms with several product pipelines for the protection of
skin, mucosa and hair for various types of cancer patients.
The VasoDynamics Pipeline
The company’s technology is currently differentiated in three formulation platforms with several product pipelines for the protection of
skin, mucosa and hair for various types of cancer patients.
Our Latest News:
VasoDynamics Undertakes Pivotal Trial Scientific Advisory Meeting with Regulatory Authority in the Netherlands to Discuss Next Steps in NG11-2 Development Programme
VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, met with the Regulatory Authority in the Netherlands, the Medicines Evaluation Board (MEB)
Our Latest News:
VasoDynamics Undertakes Pivotal Trial Scientific Advisory Meeting with Regulatory Authority in the Netherlands to Discuss Next Steps in NG11-2 Development Programme
VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, met with the Regulatory Authority in the netherlands, the Medicines Evaluation Board (MEB)
